In type 1 diabetes, autoimmune-mediated damage and destruction of insulin-producing b-cells lead to a raised blood glucose. Glucose itself is toxic and some recovery of b-cell function is expected in the honeymoon phase after insulin treatment is instituted, but it was previously believed that all b-cells will ultimately be lost. In fact, there are individuals who continue to have some functioning b-cells, even many years after the onset of type 1 diabetes (1, 2) . This raises the hope that treatment to induce replication or regeneration of b-cells could be instituted in patients with long-standing diabetes, and makes it even more imperative that means of halting autoimmunity are found.
Although nonmyeloablative autologous stem cell transplantation has been carried out, with long-term insulin independence successfully achieved in type 1 diabetes (3,4), many would feel that the risk-benefit ratio of this treatment is not acceptable for general use. Many other strategies, both nonantigen-and antigen-specific therapies, have been trialed in patients with new-onset type 1 diabetes, but none, as yet, has provided a long-term solution to the autoimmune attack on remaining b-cells (5). However, short-term slowing of b-cell loss was seen with T-cell2targeted therapy using nondepleting anti-CD3 (6,7), which was shown to temporarily reduce T cells, but, more importantly, to increase T-cell regulation. In addition, anti-CD20 treatment (rituximab) that targets B cells also temporarily slowed loss of endogenous insulin production (8, 9) , and currently there is a move to consider therapies that may be combined in order to achieve improved results.
Racine and colleagues have developed a strategy to stop autoimmunity by induction of mixed chimerism in NOD mice. The treatment uses a nonablative therapy comprising nonmyeloablative conditioning with anti-CD3 and anti-CD8 monoclonal antibodies, followed by infusion of major histocompatibility complex-mismatched bone marrow and CD4-depleted spleen cells (10) . This therapy is combined with gastrin and epidermal growth factor, and Racine et al. (11) have shown that not only is tolerance induced but also return of b-cells is demonstrated. They have previously shown that T-cell tolerance is induced by this means, but in this issue, Racine et al. (12) suggest that B-cell tolerance is also an essential component of the effectiveness of the treatment. This alteration of ratios of T1 to T2 B cells rebalances the lower T1/T2 transitional B-cell ratio in NOD mice. Increased apoptosis is seen in the host B cells, but how this is effected is not known. The authors speculate that donor B cells rather than donor cytotoxic CD8 T cells are necessary for the cell death, possibly due to the nonautoreactive donor B cells competing with the autoreactive host B cells for survival factors that include B-cell activating factor.
What is interesting about the study by Racine et al. (12) is how the normalization of B-cell subsets toward a profile that appears more like that seen in C57BL/6 mice affects diabetes and how much this contributes to the reduction of autoimmunity. The conditioning strategy used to protect from autoimmune diabetes in this study focuses on depleting T cells with antibodies and this reestablishes deletion of autoreactive T cells in the thymus (13) . Although B cells are not directly targeted by the preconditioning, this reestablishment of a "normal" B-cell compartment is clearly also playing a role in the protective effects seen. Is it mainly the reduction in the autoreactive B cells that reduces disease activity and how does the "normalization" of the ratios of B cells contribute to the maintenance of tolerance? How the repopulation of both T-and B-cell subsets occurs after depleting autoreactive T and B cells is likely to be critical to success of treatments for autoimmunity that aim to reduce pathogenic autoreactive cells and "reset" the immune system.
In respect to the anti-CD3 or anti-CD20 treatments used so far in diabetes, which have had no tangible longterm effects, it is likely that this repopulation of the T-or B-cell compartments and "resetting" of the de novo2 produced B and T cells have not been optimal. However, the process must be carefully controlled; otherwise, there is the potential for unwanted effects. For example, alemtuzumab (anti-CD52), which depletes both T and B cells, has been successfully used to treat multiple sclerosis. However, in .30% of successfully treated patients, where B cells repopulate earlier after treatment than T cells, thyroid autoimmunity is unmasked. Problems are caused by production of antibodies that stimulate the thyroidstimulating hormone receptor leading to hyperthyroidism (Graves disease) or hypothyroidism due to antithyroid antibodies (14) .
In summary, the study by Racine et al. (12) illustrates an interesting model system where depletion of both autoreactive T and B cells, combined with an active strategy to induce and "reset" both T-and B-cell tolerance after treatment, can induce long-term remission from autoimmune diabetes. The challenge will be to bring treatments 
